Late to the party, but GSK and Sanofi Covid-19 vaccines show promise 

Sanofi and GSK said there are also trials and research ongoing to see whether vaccines made by different companies can be mixed in patients.

GlaxoSmithKline and Sanofi's Covid-19 vaccine saw strong results from its phase 2 trial and will now move on to a larger phase 3 trial as the drug firms try to catch up with the competition.

Interim results from the study show a 95% to 100% seroconversion following a second injection in patients from ages 18 to 95, with no safety concerns raised.